225 related articles for article (PubMed ID: 11772257)
21. Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor.
Billah MM; Cooper N; Minnicozzi M; Warneck J; Wang P; Hey JA; Kreutner W; Rizzo CA; Smith SR; Young S; Chapman RW; Dyke H; Shih NY; Piwinski JJ; Cuss FM; Montana J; Ganguly AK; Egan RW
J Pharmacol Exp Ther; 2002 Jul; 302(1):127-37. PubMed ID: 12065709
[TBL] [Abstract][Full Text] [Related]
22. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
[TBL] [Abstract][Full Text] [Related]
23. Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast.
Zussman BD; Davie CC; Kelly J; Murdoch RD; Clark DJ; Schofield JP; Walls C; Birrell C; Webber D; Quinlan J; Ritchie SY; Carr A
Pharmacotherapy; 2001 Jun; 21(6):653-60. PubMed ID: 11401178
[TBL] [Abstract][Full Text] [Related]
24. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.
Spina D
Drugs; 2003; 63(23):2575-94. PubMed ID: 14636078
[TBL] [Abstract][Full Text] [Related]
25. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).
Barnette MS
Prog Drug Res; 1999; 53():193-229. PubMed ID: 10616299
[TBL] [Abstract][Full Text] [Related]
26. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Antoniu SA
Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
[TBL] [Abstract][Full Text] [Related]
27. The potential of PDE4 inhibitors in asthma or COPD.
Spina D
Curr Opin Investig Drugs; 2000 Oct; 1(2):204-13. PubMed ID: 11249575
[TBL] [Abstract][Full Text] [Related]
28. [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
Tatlicioğlu T
Tuberk Toraks; 2008; 56(4):472-84. PubMed ID: 19123088
[TBL] [Abstract][Full Text] [Related]
29. Update on the therapeutic potential of PDE4 inhibitors.
Dyke HJ; Montana JG
Expert Opin Investig Drugs; 2002 Jan; 11(1):1-13. PubMed ID: 11772317
[TBL] [Abstract][Full Text] [Related]
30. Roflumilast: APTA 2217, B9302-107, BY 217, BYK 20869.
Drugs R D; 2004; 5(3):176-81. PubMed ID: 15139782
[TBL] [Abstract][Full Text] [Related]
31. Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.
Houghton LA; Atkinson W; Whorwell PJ; Morris J; Murdoch RD; Cooper SM; Webber DM; Walls CM
Clin Ther; 2006 Apr; 28(4):569-81. PubMed ID: 16750468
[TBL] [Abstract][Full Text] [Related]
32. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases.
Lagente V; Martin-Chouly C; Boichot E; Martins MA; Silva PM
Mem Inst Oswaldo Cruz; 2005 Mar; 100 Suppl 1():131-6. PubMed ID: 15962112
[TBL] [Abstract][Full Text] [Related]
33. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
Banner KH; Trevethick MA
Trends Pharmacol Sci; 2004 Aug; 25(8):430-6. PubMed ID: 15276712
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of cilomilast in COPD.
Rennard S; Knobil K; Rabe KF; Morris A; Schachter N; Locantore N; Canonica WG; Zhu Y; Barnhart F
Drugs; 2008; 68 Suppl 2():3-57. PubMed ID: 19105585
[TBL] [Abstract][Full Text] [Related]
35. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far.
Giembycz MA
Monaldi Arch Chest Dis; 2002 Feb; 57(1):48-64. PubMed ID: 12174704
[TBL] [Abstract][Full Text] [Related]
36. The phosphodiesterase type IV inhibitor cilomilast decreases pro-inflammatory cytokine production from primary bronchial epithelial cells in lung transplantation patients.
Murphy DM; Ward C; Forrest IA; Pritchard G; Jones D; Stovold R; Fisher AJ; Cawston TE; Lordan JL; Corris PA
J Heart Lung Transplant; 2006 Dec; 25(12):1436-40. PubMed ID: 17178338
[TBL] [Abstract][Full Text] [Related]
37. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease.
Soto FJ; Hanania NA
Curr Opin Pulm Med; 2005 Mar; 11(2):129-34. PubMed ID: 15699784
[TBL] [Abstract][Full Text] [Related]
38. Benefit of phosphodiesterase 4 inhibitors as supplemental therapy after lung transplantation concerning their antiproliferative effects: an experimental study using a heterotopic rodent model.
Schade I; Roth-Eichhorn S; Kasper M; Kuss H; Plötze K; Funk RH; Schüler S
Transplantation; 2002 Aug; 74(3):326-34. PubMed ID: 12177610
[TBL] [Abstract][Full Text] [Related]
39. Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.
Profita M; Chiappara G; Mirabella F; Di Giorgi R; Chimenti L; Costanzo G; Riccobono L; Bellia V; Bousquet J; Vignola AM
Thorax; 2003 Jul; 58(7):573-9. PubMed ID: 12832668
[TBL] [Abstract][Full Text] [Related]
40. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease.
Barnette MS; Underwood DC
Curr Opin Pulm Med; 2000 Mar; 6(2):164-9. PubMed ID: 10741778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
